Nkarta lays off staff, senior leadership, in bid to advance autoimmune cell therapy
The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in today’s challenging financial and competitive environment.”


The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in today’s challenging financial and competitive environment.”